Clene

Clene Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Clene (CLNN) as of Nov 16, 2026 is 70.86 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 54.13 % — a change of 30.91% (higher).

Cash Conversion

70.86 %

YoY

30.91%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Clene is 2025 70.86 % . Cash Conversion Rate (OCF/Net Income) of Clene was 2024 54.13 % . It decreases by 30.91% higher compared to the previous year.

The Clene Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
74.06 USD
Jan 1, 2019
81.69 USD
Jan 1, 2020
98.19 USD
Jan 1, 2021
355.48 USD
Jan 1, 2022
130.39 USD
Jan 1, 2023
60.95 USD
Jan 1, 2024
54.13 USD
Jan 1, 2025
70.86 USD
The Clene Cash Conversion history
YEARCash ConversionYoY
70.86 %+30.91%
54.13 %-11.19%
60.95 %-53.26%
130.39 %-63.32%
355.48 %+262.02%
98.19 %+20.20%
81.69 %+10.30%
74.06 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Cash Conversion Rate (OCF/Net Income) of Clene is 70.86 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Clene changed from 54.13 % to 70.86 %, representing a 30.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Clene since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clene

All Key Metrics — Clene